OPRD1 rs569356 polymorphism has an effect on plasma norbuprenorphine levels and dose/kg-normalized norbuprenorphine values in individuals with opioid use disorder
    
Yazarlar (6)
Dilek Akyüzlü Ankara Üniversitesi, Türkiye
Doç. Dr. Selin ÖZKAN KOTİLOĞLU Kırşehir Ahi Evran Üniversitesi, Türkiye
Mustafa Danışman Ankara Training & Res Hosp AMATEM Clin, Türkiye
Ceylan Bal Ankara Yıldırım Beyazıt Üniversitesi, Türkiye
Begüm Oğur Ankara Training & Res Hosp AMATEM Clin, Türkiye
Gamze Zengin İspir Ankara Training & Res Hosp AMATEM Clin, Türkiye
Makale Türü Özgün Makale (SSCI, AHCI, SCI, SCI-Exp dergilerinde yayınlanan tam makale)
Dergi Adı ENVIRONMENTAL TOXICOLOGY AND PHARMACOLOGY (Q1)
Dergi ISSN 1382-6689 Wos Dergi Scopus Dergi
Dergi Tarandığı Indeksler SCI-Expanded
Makale Dili Türkçe Basım Tarihi 06-2023
Cilt / Sayı / Sayfa 100 / 0 / 104143–0 DOI 10.1016/j.etap.2023.104143
Makale Linki http://dx.doi.org/10.1016/j.etap.2023.104143
Özet
This study aimed to determine the effects of nine OPRM1, OPRD1 and OPRK1 polymorphisms on plasma BUP and norbuprenorphine (norBUP) concentrations and various treatment responses in a sample of 122 patients receiving BUP/naloxone. Plasma concentrations of BUP and norBUP were detected by LC–MS/MS. PCR-RFLP method was used to genotype polymorphisms. OPRD1 rs569356 GG had significantly lower plasma norBUP concentration (p = 0.018), dose- (p = 0.049) and dose/kg-normalized norBUP values (p = 0.036) compared with AA. Craving and withdrawal symptoms were significantly higher in OPRD1 rs569356 AG+GG relative to AA. There was a statistically significant difference between the OPRD1 rs678849 genotypes in the intensity of anxiety (13.5 for CT+TT and 7.5 for TT). OPRM1 rs648893 TT (18.8 ± 10.8) was significantly different to CC+CT (14.82 ± 11.3; p = 0.049) in view of the …
Anahtar Kelimeler
Opioid use disorder | Norbuprenorphine | Opioid receptors | Pharmacodynamics | Craving | Withdrawal